|1.||Kantarjian, Hagop: 16 articles (04/2012 - 02/2002)|
|2.||Cortes, Jorge: 13 articles (10/2015 - 06/2004)|
|3.||Hochhaus, Andreas: 13 articles (03/2011 - 02/2002)|
|4.||Druker, Brian J: 12 articles (01/2015 - 01/2002)|
|5.||Kantarjian, Hagop M: 10 articles (10/2015 - 03/2002)|
|6.||Baccarani, Michele: 10 articles (01/2011 - 02/2002)|
|7.||O'Brien, Stephen G: 8 articles (02/2008 - 02/2002)|
|8.||Druker, B J: 8 articles (11/2002 - 11/2000)|
|9.||Jabbour, Elias: 7 articles (12/2013 - 07/2007)|
|10.||Giles, Francis J: 7 articles (03/2011 - 07/2002)|
|1.||BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
11/15/2013 - "BCR-ABL tyrosine kinase inhibitors (TKI) have dramatically improved therapy for chronic myelogenous leukemia (CML). "
12/01/2008 - "Bcr-Abl tyrosine kinase inhibitors (TKI) are effective in inducing remissions in chronic myelogenous leukemia (CML) patients but do not eliminate primitive CML hematopoietic cells. "
04/01/2012 - "The bcr-abl tyrosine kinase inhibitors (TKIs) are the cornerstone treatment for chronic myeloid leukemia (CML). "
10/01/2015 - "Chronic myeloid leukemia (CML) is a disorder of hematopoietic stem cells caused by constitutive activation of the BCR/ABL tyrosine kinase. "
07/01/2015 - "Chronic myeloid leukemia (CML) is characterized by a constitutively active Bcr-Abl tyrosine kinase. "
05/01/2012 - "Translocation of chromosomes 9 and 22 (known as the Philadelphia chromosome) results in a fusion BCR-ABL gene that produces a dysregulated BCR-ABL tyrosine kinase protein and triggers events leading to malignant transformation. "
01/01/2008 - "The discovery of the Philadelphia chromosome followed by identification of its BCR-ABL fusion gene product and the resultant constitutively active P210 BCR-ABL tyrosine kinase, prompted the unraveling of the molecular pathogenesis of CML. "
10/01/2006 - "Our findings suggest that Eg5 is downstream of and regulated by Bcr-Abl tyrosine kinase in Philadelphia chromosome positive cells. "
05/01/2004 - "It is the result of abnormal and excess cell proliferation due to de-regulated bcr-abl tyrosine kinase activity as a result of Philadelphia chromosome. "
02/01/2002 - "In hematopoietic cells, the Bcr/Abl tyrosine kinase that is encoded by the Philadelphia chromosome translocation both stimulates proliferation and activates an anti-apoptotic program that is associated with a G2/M delay upon exposure to various apoptotic stimuli. "
|3.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
08/29/2013 - "The response of Philadelphia chromosome (Ph(+)) acute lymphoblastic leukemia (ALL) to treatment by BCR-ABL tyrosine kinase inhibitors (TKIs) has been disappointing, often resulting in short remissions typified by rapid outgrowth of drug-resistant clones. "
05/15/2006 - "Around 20% of patients with acute lymphoblastic leukemia are Philadelphia chromosome positive (Ph-positive acute lymphoblastic leukemia) and express the Bcr/Abl tyrosine kinase. "
01/01/2013 - "Development of BCR-ABL tyrosine kinase inhibitors (TKIs) have improved outcomes for patients diagnosed with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. "
07/01/2014 - "Ponatinib is a bcr-abl tyrosine-kinase inhibitor (TKI) used to treat resistant and refractory chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia that express bcr-abl. "
01/01/2014 - "In 2012, ponatinib (Iclusig(®)), an orally available pan-BCR-ABL tyrosine kinase inhibitor (TKI) developed by ARIAD Pharmaceuticals, Inc., was approved by the US Food and Drug Administration for use in resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+)ALL). "
11/01/2015 - "The prognosis of most leukemia patients treated with BCR-ABL tyrosine kinase inhibitors (TKIs) is favorable, and a more precise understanding of serious and potentially irreversible treatment-related toxicities is essential to properly inform treatment choice. "
06/01/2015 - "Despite remarkable success in controlling CML at chronic phase by Bcr-Abl tyrosine kinase inhibitors (TKIs), a significant proportion of CML patients treated with TKIs develop drug resistance due to the inability of TKIs to kill leukemia stem cells (LSCs) that are responsible for initiation, drug resistance, and relapse of CML. "
11/01/2008 - "Bcr-Abl tyrosine kinase (TK) inhibitors are promising therapeutic agents for Bcr-Abl-positive (Bcr-Abl(+)) leukemias. "
04/15/2006 - "Breakpoint cluster region/Abelson (BCR/ABL) tyrosine kinase enhances the ability of leukemia cells to infiltrate various organs. "
08/19/2005 - "The Bcr-Abl tyrosine kinase causes different forms of leukemia in humans. "
|5.||Blast Crisis (Blast Phase)
04/01/2015 - "Due to the high efficacy of BCR-ABL tyrosine kinase inhibition (TKI) in chronic phase (CP) chronic myeloid leukemia (CML), the frequency of blast crisis (BC) is greatly reduced compared to the pre-TKI era. "
12/01/2004 - "This study was to evaluate efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on CML in blast phase. "
10/01/2006 - "Patients with blast crisis (BC) CML frequently become resistant to Imatinib, a Bcr-Abl tyrosine kinase-targeting agent. "
06/19/2006 - "However, accelerated or blast-crisis phase CML patients and Ph+ ALL patients often relapse due to drug resistance resulting from the emergence of imatinib-resistant point mutations within the BCR-ABL tyrosine kinase domain. "
07/01/2003 - "These findings suggest that STI571 does not effectively block signaling molecules downstream of the BCR-ABL tyrosine kinase in some cases of CML blast crisis."
|3.||4- methyl- N- (3- (4- methylimidazol- 1- yl)- 5- (trifluoromethyl)phenyl)- 3- ((4- pyridin- 3- ylpyrimidin- 2- yl)amino)benzamide (nilotinib)
|4.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|5.||dasatinib (BMS 354825)
|6.||Telomerase (Telomerase Reverse Transcriptase)
|7.||Interferon Type I
|9.||aurora kinase (aurora A kinase)
|10.||Proteins (Proteins, Gene)
|1.||Stem Cell Transplantation
|2.||Molecular Targeted Therapy